
This review evaluates past and present clinical trials, as well as the current preclinical drug candidates focused on treating Alzheimer's disease (AD), in order to better assess the trends in AD drug discovery in context with specific drug mechanisms. The author begins by presenting a summary of the results of over 160 clinical trials targeted at AD, of which 52% have either failed to meet clinical endpoints or stalled (defined for the purpose of this review as no clinical or publicly mentioned progress for at least 3 years). The author postulates that many of the current clinical approaches fail to sufficiently regulate the amyloid cascade that includes, but is not limited to, the production of soluble β-amyloid precursor protein, β-amyloid and/or amyloid precursor protein intracellular domain and including activation of the tau cascade, ultimately translating to no improvement in cognitive function. To support this argument, the author compares clinical results and peer-reviewed opinions to postulate that appropriately focused multifunctional or dual pathway drugs could make the optimal candidate(s) for further investigations.
In this white paper, Thomson Reuters provides a snapshot of the imaging biomarkers at use in research and development, and the clinic; examines key technical and commercialization challenges; and identifies promising avenues for progress in the field with insight from experts from industry and academia.
Chronic inflammation is increasingly regarded not just as a consequence of a continuous infectious hazard, but also as an integral part of many noninfectious diseases such as autoimmune disorders, diabetes or cardiovascular disease. Thus, it is not surprising that some hormonal systems, like the renin-angiotensin system (RAS), which were originally described in the context of cardiovascular disease have also turned out to be major regulators of the inflammatory response. This review focuses on the role of the RAS in inflammation, with particular emphasis on the role of the angiotensin AT(2) receptor. While the proinflammatory features of the angiotensin AT(1) receptor are well established, most current evidence supports an anti-inflammatory role for AT(2) receptor. However, data on this receptor in inflammation are still rather sparse and are somewhat controversial. This article will discuss the principal mechanisms of AT(2) receptor-coupled interference with proinflammatory pathways as well as data derived from animal models of specific diseases. Finally, it will give a brief outlook into new possibilities in AT(2) receptor research and in the potential utilization of AT(2) receptor stimulation as a novel pharmacological concept in anti-inflammation.
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system, activating ionotropic (iGlu) and metabotropic (mGlu) glutamate receptors. Targeting iGlu receptors has proven difficult, as these receptors play such a critical role in fast synaptic transmission. In recent years, there has been a switch in the focus of the pharmaceutical industry to target mGlu receptors, as these receptors have a more modulatory role in the brain. Eight subtypes of the G protein-coupled mGlu receptors have been cloned and classified into three groups according to their second messenger association, sequence homology and agonist selectivity. Group I (mGlu(1) and mGlu(5)) receptors are positively coupled to phosphatidylinositol (PO hydrolysis, while group II (mGlu(2) and mGlu(3)) and group III (mGlu(4), mGlu(6), mGlu(7) and mGlu(8)) receptors are negatively coupled to adenylate cyclase and thought to act as presynaptic autoreceptors, regulating glutamate transmission. There has been rapid progress in understanding the biology of mGlu receptors and their function in the central nervous system (CNS), and the field now has highly potent and selective ligands for many of the mGlu receptor subtypes. Pharmacological tools include both orthosteric and allosteric agonists and antagonists. These molecules have been explored across a range of CNS conditions, the findings of which will be discussed briefly in this review. Recently, some of the most promising molecules have progressed into clinical trials (mGlu(2/3) receptor agonists for the treatment of anxiety and schizophrenia and mGlu(5) receptor antagonists for acute migraine and L-DOPA-induced dyskinesia) and achieved proof of concept. These encouraging results suggest mGlu receptors as novel drug targets with application in a range of psychiatric and neurological conditions.